Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): A commentary

Theoretical Biology and Medical Modelling

Volumn 5, Issue , 2008, Pages

  Blum, Kenneth ^a,d,e,g   Chen, Amanda Lih Chuan ^b   Chen, Thomas Jh ^b   Braverman, Eric R ^c,g   Reinking, Jeffrey ^b   Blum, Seth H ^d   Cassel, Kimberly ^d   Downs, Bernard W ^e   Waite, Roger L ^e   Williams, Lonna ^e   Prihoda, Thomas J ^f   Kerner, Mallory M ^g   Palomo, Tomas ^h   Comings, David E ⁱ   Tung, Howard ^j   Rhoades, Patrick ^k   Oscar Berman, Marlene ^l  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Synaptamine Inc   (United States)

^e LifeGen Inc   (United States)

^f University of Texas Health Science Center at San Antonio   (United States)

^g Path Medical Research Foundation   (United States)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^j UCSD MEDICAL CENTER   (United States)

^k Central Valley Pain Management and Wellness Modesto   (United States)

^l BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; CATECHOL METHYLTRANSFERASE; CHROMIUM PICOLINATE; DOPAMINE; DOPAMINE RECEPTOR; GABAPENTIN; GLUTAMINE; NUTRACEUTICAL; PHENYLALANINE; PICOLINIC ACID; PLACEBO; RIMONABANT; SAAVE; SEROTONIN; SEROTONIN RECEPTOR; SYNAPATMINE; TROPAMINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR BLOCKING AGENT;

ADDICTION; ALCOHOLISM; AMINO ACID DEFICIENCY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; COCAINE DEPENDENCE; DOPAMINE RELEASE; GENE THERAPY; MESOLIMBIC DOPAMINERGIC SYSTEM; NEGATIVE FEEDBACK; NEUROCHEMISTRY; NUCLEUS ACCUMBENS; NUTRIGENOMICS; OBESITY; OVERNUTRITION; PATHOLOGICAL GAMBLING; RECEPTOR UPREGULATION; RELAPSE; REWARD; SUICIDAL IDEATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ANIMAL; GENETICS; GENOMICS; HUMAN; MENTAL DISEASE; METABOLISM; PSYCHOLOGICAL ASPECT; REVIEW; SYNDROME; TIME;

RODENTIA;

ANIMALS; DOPAMINE ANTAGONISTS; GENOMICS; HUMANS; MENTAL DISORDERS; REWARD; SYNDROME; TIME FACTORS;

EID: 62149107080     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-5-24     Document Type: Article

References (77)

1. Genomics and the future of pharmacotherapy in psychiatry. AK Malhotra T Lencz CU Correll JM Kane, Int Rev Psychiatry 2007 19 523 530 17896232 (Pubitemid 47493739)
2. Addiction and the Brain Antireward System. GF Koob M Le Moal, Annu Rev Psychol 2008 59 29 53 18154498
3. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. ND Volkow JS Fowler GJ Wang RZ Goldstein, Neurobiol Learn Mem 2002 78 610 624 12559839 (Pubitemid 36268682)
4. DRD2/ANKK1 TaqI polymorphism and smoking behavior of Egyptian male cigarette smokers. GN Radwan ME Setouhy MK Mohamed MA Hamid E Israel SA Azem O Kamel CA Loffredo, Nicotine Tob Res 2007 9 1325 1329 18058350 (Pubitemid 350218024)
5. Dopamine genes and pathological gambling in discordant sib-pairs. DS da Silva Lobo HP Vallada J Knight SS Martins H Tavares V Gentil JL Kennedy, J Gambl Stud 2007 23 421 33 17394052
6. Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. P Kirsch M Reuter D Mier T Lonsdorf R Stark B Gallhofer D Vaitl J Hennig, Neurosci Lett 2006 405 196 201 16901644 (Pubitemid 44189725)
7. Genotype combinations for monoamine oxidase-B intron 13 polymorphism and dopamine D2 receptor TaqIB polymorphism are associated with ever-smoking status among men. P Costa-Mallen LG Costa H Checkoway, Neurosci Lett 2005 385 158 162 15955630 (Pubitemid 40961654)
8. Association between the DRD2 A1 allele and opium addiction in the Iranian population. M Shahmoradgoli Najafabadi M Ohadi MT Joghataie F Valaie Y Riazalhosseini H Mostafavi F Mohammadbeigi H Najmabadi, Am J Med Genet B Neuropsychiatr Genet 2005 134B 1 39 41 15704216 (Pubitemid 40411107)
9. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. GE Swan LM Jack AM Valdes HZ Ring CC Ton SJ Curry T McAfee, Health Psychol 2007 26 361 368 17500623 (Pubitemid 46763197)
10. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. K Xu D Lichtermann RH Lipsky P Franke X Liu Y Hu L Cao SG Schwab DB Wildenauer CH Bau E Ferro W Astor T Finch J Terry J Taubman W Maier D Goldman, Arch Gen Psychiatry 2004 61 597 606 15184239 (Pubitemid 38747314)
11. Opiate-like effects of sugar on gene expression in reward areas of the rat brain. R Spangler KM Wittkowski NL Goddard NM Avena BG Hoebel SF Leibowitz, Brain Res Mol Brain Res 2004 124 134 142 15135221 (Pubitemid 38591565)
12. The A1 allele of the DRD2 gene (TaqI A polymorphisms) is associated with antisocial personality in a sample of alcohol-dependent patients. G Ponce MA Jimenez-Arriero G Rubio J Hoenicka I Ampuero JA Ramos T Palomo, Eur Psychiatry 2003 18 356 360 14643564 (Pubitemid 37484539)
13. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. MR Spitz H Shi F Yang KS Hudmon H Jiang RM Chamberlain CI Amos Y Wan P Cinciripini WK Hong X Wu, J Natl Cancer Inst 1998 90 358 363 9498485 (Pubitemid 28131003)
14. Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. DE Comings D Muhleman R Gysin, Biol Psychiatry 1996 40 368 372 8874837 (Pubitemid 26301067)
15. Food reinforcement, the dopamine D2 receptor genotype, and energy intake in obese and nonobese humans. LH Epstein JL Temple BJ Neaderhiser RJ Salis RW Erbe JJ Leddy, Behav Neurosci 2007 121 877 889 17907820 (Pubitemid 350051291)
16. Effects of ethanol on midbrain neurons: role of opioid receptors. C Xiao J Zhang K Krnjeviæ JH Ye, Alcohol Clin Exp Res 2007 31 1106 1113 17577392 (Pubitemid 46934389)
17. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. K Blum ER Braverman JM Holder JF Lubar VJ Monastra D Miller JO Lubar TJ Chen DE Comings, J Psychoactive Drugs 2000 32 Suppl i iv 11280926 (Pubitemid 32005730)
18. Reward deficiency syndrome: genetic aspects of behavioral disorders. DE Comings K Blum, Prog Brain Res 2000 126 325 341 11105655 (Pubitemid 35461297)
19. Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency Syndrome. A Bowirrat M Oscar-Berman, Am J Med Genet B Neuropsychiatr Genet 2005 132B 1 29 37 15457501 (Pubitemid 40066191)
20. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? AI Green SV Zimmet RD Strous JJ Schildkraut, Harv Rev Psychiatry 1999 6 287 296 10370435 (Pubitemid 29132022)
21. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. ND Volkow GJ Wang F Telang JS Fowler J Logan M Jayne Y Ma K Pradhan C Wong, J Neurosci 2007 27 12700 12706 18003850 (Pubitemid 350127825)
22. The nucleus accumbens and reward: neurophysiological investigations in behaving animals. RM Carelli, Behav Cogn Neurosci Rev 2002 1 281 296 17712985
23. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. T Pohjalainen JO Rinne K Ngren P Lehikoinen K Anttila EK Syvälahti J Hietala, Mol Psychiatry 1998 3 256 260 9672901 (Pubitemid 28266335)
24. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. EP Noble K Blum T Ritchie A Montgomery PJ Sheridan, Arch Gen Psychiatry 1991 48 648 654 2069496
25. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. K Blum TJ Chen B Meshkin RL Waite BW Downs SH Blum JF Mengucci V Arcuri ER Braverman T Palomo, Med Hypotheses 2007 69 1054 1060 17467918 (Pubitemid 47440164)
26. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. K Blum PJ Sheridan RC Wood ER Braverman TJ Chen JG Cull DE Comings, J R Soc Med 1996 89 396 400 8774539 (Pubitemid 26245635)
27. Agonists and antagonists differentially regulate the high affinity state of the D2L receptor in human embryonic kidney 293 cells. VA Boundy MA Pacheco W Guan PB Molinoff, Mol Pharmacol 1995 48 956 964 7476927
28. Differential coupling of rat D2 dopamine receptor isoforms expressed in Spodoptera frugiperda insect cells. VA Boundy L Lu PB Molinoff, J Pharmacol Exp Ther 1996 276 784 794 8632351 (Pubitemid 126660522)
29. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. BR Lawford RM Young JA Rowell J Qualichefski BH Fletcher K Syndulko T Ritchie EP Noble, Nat Med 1995 1 337 341 7585063
30. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. R Christensen PK Kristensen EM Bartels H Bliddal A Astrup, Lancet 2007 370 1671 1672 18022023 (Pubitemid 350100788)
31. 97(3). XQ Peng X Li J Li PV Ramachandran PD Gagare D Pratihar CR Ashby Jr EL Gardner ZX Xi, Drug Alcohol Depend 2008 97 3 207 15 18065162
32. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. RB Rothman BE Blough MH Baumann, AAPS J 2007 9 E1 10 17408232 (Pubitemid 46157624)
33. Reviewing the role of putative candidate genes in " Neurobesigenics" a clinical subtype of Reward Deficiency Syndrome (RDS). TJH Chen K Blum G Kaats E Braverman D Pullin BW Downs M Martinez-Pons SH Blum J Mengucci D Bagchi M Bagchi A Robarge B Meshkin V Arcuri M Varshavskiy A Notaro DE Comings L White, Gene Ther Mol Biol 2007 11 61 74 (Pubitemid 47505881)
34. Genotrim, a DNA -customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). K Blum TJ Chen B Meshkin BW Downs CA Gordon S Blum JF Mengucci ER Braverman V Arcuri R Deutsch MM Pons, Medical Hypotheses 2007 68 844 852 17071010 (Pubitemid 46136783)
35. Synaptamine (Sg8839): an amino-acid enkephalinase inhibition nutraceutical improves recovery of alcoholics, a subtype of Reward Deficiency Syndrome (RDS). K Blum TJH Chen BW Downs B Meshkin SH Blum M Martinez-Pons JF Mengucci RL Waite V Arcuri M Varshavskiy ER Braverman, Trends in Applied Sciences Res 2007 2 132 138
36. Reward Deficiency Syndrome in Obesity: a preliminary cross-sectional trial with a Genotrim variant. K Blum TJH Chen B Meshkin BW Downs CA Gordon SH Blum JF Mengucci ER Braverman V Arcuri M Varshavskiy R Deutsch M Martinez-Pons, Adv Ther 2006 23 1040 1051 17276971 (Pubitemid 46341061)
37. Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study. TJH Chen K Blum G Kaats ER Braverman A Eisenberg M Sherman K Davis DE Comings R Wood D Pullin V Arcuri M Varshavskiy JF Mengucci SH Blum BW Downs B Meshkin RL Waite L Williams J Schoolfield L White, Gene Ther Mol Biol 2007 11 161 170
38. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. TJ Chen K Blum JT Payte J Schoolfield D Hopper M Stanford ER Braverman, Med Hypotheses 2004 63 538 548 15288384 (Pubitemid 38993627)
39. Gene\Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. TJ Chen K Blum RL Waite B Meshkin J Schoolfield BW Downs EE Braverman V Arcuri M Varshavskiy SH Blum J Mengucci C Reuben T Palomo, Adv Ther 2007 24 402 414 17565932 (Pubitemid 46988385)
40. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). K Blum TJ Chen B Meshkin BW Downs CA Gordon S Blum JF Mengucci ER Braverman V Arcuri R Deutsch MM Pons, Med Hypotheses 2007 68 844 852 17071010 (Pubitemid 46136783)
41. Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders. RJ Brown K Blum MC Trachtenberg, J Psychoactive Drugs 1990 22 173 187 2374070 (Pubitemid 20245961)
42. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. K Blum MC Trachtenberg CE Elliott ML Dingler RL Sexton AI Samuels L Cataldie, Alcohol 1988 5 481 493 3072969 (Pubitemid 19273817)
43. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. K Blum MC Trachtenberg JC Ramsay, Int J Addict 1988 23 991 998 2906910 (Pubitemid 19007703)
44. Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. K Blum MC Trachtenberg, J Psychoactive Drugs 1988 20 297 313 3069987 (Pubitemid 19006841)
45. Enhancement of attention processing by Kantroll in healthy humans: a pilot study. JF DeFrance C Hymel MC Trachtenberg LD Ginsberg FC Schweitzer S Estes TJ Chen ER Braverman JG Cull K Blum, Clin Electroencephalogr 1997 28 68 75 9137870 (Pubitemid 27198114)
46. Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. K Blum MC Trachtenberg DW Cook, Curr Ther Res 1990 43 217 233 (Pubitemid 20248047)
47. Clinical evidence for effectiveness of PhenCal in maintaining weight loss in an open-label, controlled, 2 year study. K Blum JG Cull TJH Chen S Garcia-Swan JM Holder RC Wood ER Braverman LR Bucci MC Trachtenberg, Curr Ther Res 1997 58 745 763 (Pubitemid 27497622)
48. Overexpression of dopamine D2 receptors reduces alcohol self-administration. PK Thanos ND Volkow P Freimuth H Umegaki H Ikari G Roth DK Ingram R Hitzemann, J Neurochem 2001 78 1094 1103 11553683 (Pubitemid 32823158)
49. D2 dopamine receptor gene and obesity. EP Noble RE Noble T Ritchie DK Grandy RS Sparks, J Eating Disorders 1994 15 205 217
50. Genetic and environmental factors in relative body weight and human adiposity. HH Maes Mc Neale IJ Eaves, Behav Gen 1997 27 4 325 351 (Pubitemid 27415169)
51. Twin study of genetic and environmental influences on adult body size, shape, and composition. K Schoushoe PM Visscher B Erbas KO Kyvik Jl Hopper JE Henriksen BL Heitman, Int J Obes Relat Metab Disord 2004 28 1 39 48 14610529 (Pubitemid 38141989)
52. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. K Blum ER Braverman RC Wood J Gill C Li TJ Chen M Taub AR Montgomery PJ Sheridan JG Cull, Pharmacogenetics 1996 6 297 305 8873216 (Pubitemid 26288620)
53. The dopamine D2 receptor (DRD2) as a major in obesity and height. DE Comings SD Flanagan G Dietz D Muhlman E Knell R Gysin, Biochem Med Metab Biol 1993 50 176 185 8260195 (Pubitemid 23295784)
54. Genetic variants of the human obesity (OB) gene : association with body mass index in young women : psychiatric symptoms and interactions with the dopamine D2 receptor(DRD2) gene. DE Comings R Gade JP McMurray D Muhlman P Johnson R Verde WR Peters, Mol Psychiatry 1996 1 325 335 9118359 (Pubitemid 126441317)
55. DNA-Customized Genotrim induces significant reductions in weight, appetite and sugar cravings in the D.I.E.T. study: Polymorphic correlates involving five candidate genes in Obesity, a clinical subtype of Reward Deficiency Syndrome (RDS). K Blum B Meshkin TJ Prihoda BW Downs RL Waite ER Braverman L White, Presented at the Natural Products Association Scientific Session, 2007, July 21, Las Vegas, NV (abstract)
56. Addiction and the Brain Antireward System. GF Koob M Le Moal, Annu Rev Psychol 2008 59 29 53 18154498
57. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. ND Volkow JS Fowler GJ Wang RZ Goldstein, Neurobiol Learn Mem 2002 78 610 624 12559839 (Pubitemid 36268682)
58. Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. DE Comings TJ Chen K Blum JF Mengucci SH Blum B Meshkin, Theor Biol Med Model 2005 23 2 50 (Pubitemid 43163297)
59. Attention-Deficit-Hyperactivity Disorder and Reward Deficiency Syndrome. K Blum ALC Chen ER Braverman DE Comings TJH Chen V Arcuri SH Blum BW Meshkin Downs RL Waite A Notaro J Lubar L Williams TJ Prihoda T Palomo M Oscar Berman, J Neuropsychiat Diseas Diag Treatment
60. Does dopaminergic reward system contribute to explaining comorbidity obesity and ADHD? LL Liu BM Li J Yang YW Wang, Med Hypotheses 2008 70 6 1118 20 18158220
61. Obesity, attention deficit-hyperactivity disorder and the dopaminergic reward system. BC Campbell D Eisenberg, Coll Antropol 2007 31 33 38 17600916
62. A prospective study of alcoholism and the risk of Parkinson's disease. MA Hernán G Logroscino LA Rodríguez, J Neurol 2004 251 Suppl 7 vII14 7 15505749 (Pubitemid 39506527)
63. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. JF Chen VJ Aloyo B Weiss, Neuroscience 1993 54 669 80 8101360 (Pubitemid 23171327)
64. Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa. G Linazaroso N van Blercom A Lasa, Neurologia 2004 19 117 27 15088161 (Pubitemid 38508387)
65. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. T Witjas C Baunez JM Henry M Delfini J Regis AA Cherif JC Peragut JP Azulay, Mov Disord 2005 20 1052 5 15858803 (Pubitemid 41419526)
66. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. B Le Foll SR Goldberg, J Pharmacol Exp Ther 2005 312 875 83 15525797 (Pubitemid 40293744)
67. The debate over dopamine's role in reward: the case for incentive salience. KC Berridge, Psychopharmacology (Berl) 2007 191 391 431 17072591 (Pubitemid 46355895)
68. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. A Alcaro R Huber J Panksepp, Brain Res Rev 2007 56 283 321 17905440 (Pubitemid 350176598)
69. Genetic loading on human loving styles. E Emanuele N Brondino S Pesenti S Re D Geroldi, Neuro Endocrinol Lett 2007 28 815 21 18063936
70. Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype. CA Boettiger JM Mitchell VC Tavares M Robertson G Joslyn M D'Esposito HL Fields, J Neurosci 2007 27 14383 14391 18160646
71. Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. JD Salamone MS Cousins BJ Snyder, Neurosci Biobehav Rev 1997 21 341 59 9168269 (Pubitemid 27225155)
72. Naloxone-induced inhibition of ethanol dependence in mice. K Blum S Futterman JE Wallace HA Schwertner, Nature 1977 265 49 51 556802 (Pubitemid 8004305)
73. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. JL Snyder TG Bowers, Am J Drug Alcohol Abuse 2008 34 449 61 18584575
74. The role of the endogenous cannabinoid system in drug addiction. D Parolaro T Rubino, Drug News Perspect 2008 21 5 149 157 18560613
75. Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of a pilot study in the Netherlands. K Blum ALC Chen TLC Chen P Rhoades P Prihoda BW Downs D Bagchi M Bagchi S Blum L Williams ER Braverman M Kerner RL Waite B Quirk L White, Gene Therapy and Molecular Biology 2008
76. LG839 (an experimental DNA-Customized neutraceutical): Anti-obesity effects and polymorphic gene correlates of Reward Deficiency Syndrome. K Blum ALC Chen TJH Chen P Rhoades P Prihoda BW Downs RL Waite L Williams ER Braverman D Braverman Arcuri M Kerner SH Blum J Reinking T Palomo, Adv Ther
77. MPP(+) and glutamate in the degeneration of nigral dopaminergic neurons. S Sawada S Shimohama, Parkinsonism Relat Disord 1999 5 4 209 215 18591142 (Pubitemid 29408677)